NGM · Biotechnology

Jyong Biotech Ltd. Ordinary Shares (MENS) Stock

$2.37 +0.53% NGM: MENS Healthcare

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system.

Valuation

MetricValue
Price$2.37
Market Cap$180.37M
P/E Ratio-27.28
P/B Ratio-7.03
P/S Ratio0.00
EPS (TTM)$-0.04
52-Week High$67.00
52-Week Low$1.43
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE19.39%
ROA-22.49%
ROCE18.59%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.74
Current Ratio0.62

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-2.0M$-3.0M$-3.0M$-2.0M$-3.0M
Net Profit$-4.0M$-7.0M$-4.0M$-3.0M$-5.0M
EPS$-0.06$-0.09$-0.06$-0.04$-0.06
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$9.0M$9.0M$8.0M$6.0M$21.0M
Total Liabilities$33.0M$38.0M$42.0M$43.0M$46.0M
Cash$1.0M$1.0M$0$0$1.0M
Borrowings$12.0M$14.0M$17.0M$18.0M$19.0M

Latest News

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention PR Newswire · Jul 3, 2026 Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview PR Newswire · Jun 1, 2026 Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 GlobeNewswire · May 15, 2026 Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio PR Newswire · Apr 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-3.0M$-3.0M$-4.0M$-3.0M
Investing Cash Flow$-1.0M$1.0M$0$0$-14.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-5.0M$2.0M$-1.0M$-2.0M$1.0M
Free Cash Flow$-2.0M$-3.0M$-3.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.58
EV / EBITDA-76.94
FCF Yield-1.66%
Quick Ratio0.46
Interest Coverage-1.00
Return 1Y-75.70%
Return 3Y—
Return 5Y—

Ownership

Insiders Held62.20%
Institutions Held0.71%
Institutions Float Held1.89%
Institutional HolderSharesReport Date
Blackrock Inc.258,7602026-03-31
Geode Capital Management, LLC64,2322026-03-31
UBS Group AG37,3632026-03-31
China Universal Asset Management Co., Ltd.13,1732026-03-31
Vanguard Personalized Indexing Management, LLC13,9272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $134.19 +0.06% -16.89 $8.30B 0.00%
CELC $92.49 +5.44% -91.68 $4.51B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%

About Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

Jyong Biotech Ltd. Ordinary Shares is led by CEO Fu-Feng Kuo, employs 31 people, headquartered in TW, publicly traded since 2025.

Jyong Biotech Ltd. Ordinary Shares (MENS) stock trades at $2.37 with a market capitalization of $180.37M. The stock is valued at a price-to-earnings (P/E) ratio of -27.28, price-to-book of -7.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.43 and $67.00, and currently trades 96.5% below its 52-week high.

On profitability, Jyong Biotech Ltd. Ordinary Shares generates a return on equity (ROE) of 19.39%, above the typical market average, return on capital employed of 18.59%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.jyongbio.com/

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides